Seattle Genetics, Inc. (NASDAQ:SGEN) Director Marc E. Lippman sold 3,000 shares of the business’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $58.07, for a total value of $174,210.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Seattle Genetics, Inc. (SGEN) traded up $0.50 during midday trading on Friday, reaching $59.79. The company’s stock had a trading volume of 665,770 shares, compared to its average volume of 973,109. Seattle Genetics, Inc. has a 52 week low of $45.31 and a 52 week high of $73.91.

Seattle Genetics (NASDAQ:SGEN) last issued its quarterly earnings data on Thursday, October 26th. The biotechnology company reported ($0.19) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.23. Seattle Genetics had a negative return on equity of 32.41% and a negative net margin of 26.53%. The company had revenue of $135.29 million for the quarter, compared to analysts’ expectations of $112.76 million. During the same period in the previous year, the firm posted ($0.23) earnings per share. The firm’s revenue for the quarter was up 27.3% on a year-over-year basis. equities analysts predict that Seattle Genetics, Inc. will post -0.93 EPS for the current fiscal year.

WARNING: “Seattle Genetics, Inc. (SGEN) Director Marc E. Lippman Sells 3,000 Shares” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/11/17/seattle-genetics-inc-sgen-director-marc-e-lippman-sells-3000-shares.html.

Hedge funds and other institutional investors have recently modified their holdings of the business. Quantbot Technologies LP increased its stake in Seattle Genetics by 116.5% during the third quarter. Quantbot Technologies LP now owns 2,654 shares of the biotechnology company’s stock worth $144,000 after acquiring an additional 1,428 shares during the last quarter. First Manhattan Co. increased its stake in Seattle Genetics by 31.3% during the second quarter. First Manhattan Co. now owns 3,150 shares of the biotechnology company’s stock worth $162,000 after acquiring an additional 750 shares during the last quarter. Bristlecone Advisors LLC bought a new stake in Seattle Genetics during the third quarter worth approximately $180,000. Virtu Financial LLC bought a new stake in Seattle Genetics during the third quarter worth approximately $203,000. Finally, Meeder Asset Management Inc. increased its stake in Seattle Genetics by 1,580.9% during the second quarter. Meeder Asset Management Inc. now owns 3,950 shares of the biotechnology company’s stock worth $205,000 after acquiring an additional 3,715 shares during the last quarter. 98.45% of the stock is currently owned by institutional investors.

Several equities analysts have recently commented on the company. Oppenheimer Holdings, Inc. assumed coverage on Seattle Genetics in a research report on Tuesday, October 10th. They issued a “hold” rating on the stock. Cantor Fitzgerald set a $46.00 price objective on Seattle Genetics and gave the company a “hold” rating in a research report on Tuesday, October 10th. Cann assumed coverage on Seattle Genetics in a research report on Wednesday, November 8th. They issued a “hold” rating on the stock. Jefferies Group LLC restated a “buy” rating and issued a $53.00 price objective on shares of Seattle Genetics in a research report on Thursday, July 27th. Finally, Bank of America Corporation upgraded Seattle Genetics from an “underperform” rating to a “neutral” rating in a research report on Friday, October 27th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. Seattle Genetics currently has a consensus rating of “Hold” and a consensus price target of $63.53.

Seattle Genetics Company Profile

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Stock Ratings for Seattle Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics Inc. and related stocks with our FREE daily email newsletter.